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ABSTRACT 
Neuropathic pain is defined as “Pain is observed as disease of the somatosensory nervous system.” The cause of pain is very wide-ranging and 
may certainly be idiopathic. Two nerve damage classifications have been described and they are outlined. These are first line and second line.  
Neuropathic pain is generated by electrical hyperactivity of neurons along the pain pathways. The sensory pathway consists of at least three 
neurons, and lesions anywhere along the pathway can lead to neuropathic pain. A successful clinical management for neuropathic pain requires 
balancing the advantages and side effects of available drugs, lifestyle interventions, and treating the underlying cause if possible  for the 
management of neuropathic pain requires various lines of treatment i.e first line and second line treatment which includes various types of 
drugs. 
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INTRODUCTION 
Neuropathic pain is defined as “Pain is observed as disease 
of the somatosensory nervous system.” The cause of pain is 
very wide-ranging and may certainly be idiopathic. 
Neuropathic pain may often be doubted or identified 
through some of the classical descriptions of the pain that 
patients can give, such as: ‘burning, shooting, tingling, 
electric shocks, sharp, nagging, walking on hot coals’1-6  
Nerve pain or neuropathic pain is originated due to damage 
to nerve or nerve disease. There may be sensitivity to the 
skin (allodynia) when light touch or clothes rubbing on the 
area can cause severe pain. In the area of pain there may be 
chances of numbness.3 The hallmarks of neuropathic pain 
are chronic diseases like hyperalgesia and allodynia. 
Allodynia may be defined as pain resulting from a stimulus 
that ordinarily does not elicit a painful reaction (e.g., light 
touch). An increased sensitivity to normally painful stimuli is 
mainly called as Hyperalgesia. Within the area of injury 
immediately primary hyperalgesia is caused by sensitization 
of C-fibers. Secondary hyperalgesia, caused by sensitization 
of dorsal horn neurons, occurs in the undamaged area 
surrounding the injury1,2  an injury to a nerve can result in a 
problematic with the muscle or during sensation is loss. In 
some people it can also cause pain. Two nerve damage 
classifications have been described and they are outlined. A 
first degree injury or neurapraxia will recuperate quickly 
within days after the injury or it may take up to 3 months. 
The recoveries are going to be complete with no lasting 
muscle or sensory drawback. A second degree injury or 
axonotmesis will also have complete recovery however the 
recovery will be much slower than a first degree injury7. 
Neuropathic pain is associated with increased drug 
prescriptions and visits to health care providers. The 
estimation of the incidence and prevalence of neuropathic 
pain has been difficult because of the lack of simple 
diagnostic criteria for large epidemiological surveys in the 
general population. Thus, the prevalence of neuropathic pain 
in the chronic pain population has mainly been estimated on 
the basis of studies conducted by specialized centers with a 
focus on specific conditions, such as post herpetic neuralgia, 
painful diabetic polyneuropathy, post-surgery neuropathic 
pain, multiple sclerosis, spinal cord injury, stroke and 
cancer. 
The recent development of simple screening tools in the 
form of questionnaires has helped conduct several large 
epidemiological surveys in different countries (the United 
Kingdom, the United States, France and Brazil) and provided 
valuable new information on the general prevalence of 
neuropathic pain. In using screening tools, such as the 
Douleur Neuropathique 4 questions or the Leeds 
Shewale et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):820-824 
ISSN: 2250-1177                                                                                  [821]                                                                                      CODEN (USA): JDDTAO 
Assessment of Neuropathic Symptoms and Signs (LANSS) 
pain scale, the prevalence of chronic pain with neuropathic 
characteristics has been estimated to be in the range of 7–
10%.8 
ANATOMY  
Nerves are connected to your brain and spinal cord to the 
muscles and skin giving you movement and feeling. If there 
is an damage or injury to the nerve, then there will be an 
disturbance in the information being conveyed to the skin or 
muscles  from the brain. In the arm and the legs there are 
larger nerves present the size of that nerves are like pencil 
and these nerves are made up of tens of thousands of nerve 
fibers and these are similar to the telephone cable and these 
nerve fibers are grouped togetherly in fascicles. Some nerves 
like the median and ulnar nerve in your arm have motor and 
sensory fascicles giving you movement and feeling to your 
hand.8 
NEUROPATHIC PAIN MECHANISMS 
Neuropathic pain is generated by electrical excitation of 
neurons between the pain pathways. The sensory pathway 
consists of at least three neurons, and lesions anywhere 
along the pathway can lead to neuropathic pain. Neuropathic 
pain (neural plasticity) caused by changes in the expression 
of neuronal ion channels and receptors, synaptic 
connectivity, and anatomy 1 
 
Figure 1: Mechanism of Neuropathic pain 
1.  Central Mechanisms in Neuropathic Pain 
With repeated or sufficiently intense stimulation, spinal and 
supraspinalnociceptive pathways can become sensitized to 
subsequent stimuli. With persistent nociceptive input], like 
that seen in peripheral neuropathy, this central sensitization 
becomes maladaptive. IASP gives definition of central 
sensitization as “increased responsiveness of nociceptive 
neurons in the central nervous system to their normal or sub 
threshold afferent input”. At the synapse of second-order 
neurons, this increased responsiveness can involve changes 
in calcium permeability, receptor overexpression, and 
synapse location also promoting a chronic pain state are 
microglia, whose hyperactivation triggers the release of 
pain-promoting mediators . Another major contributor to 
ongoing pain is in supraspinal regions, the resulting 
misbalance between descending facilitation and inhibition. 
Maladaptive subcortical and cortical plasticity also 
contributes to painful interpretation of incoming signals, 
with the ultimate result promoting a chronic pain state.6,12 
2.  Peripheral Mechanisms in Neuropathic Pain 
Chronic neuropathic pain through multiple routes is caused 
due to peripheral nerve damage. While the insult may be 
localized, the responses that lead to chronic pain are not. 
Peripheral terminals of pain-processing unmyelinated C 
fibers and thinly-myelinated Aδ fibers can spur the 
development of neuropathic pain after being affected by 
metabolic damage, toxins, medications, cytokines, and other 
inflammatory mediators resulting in fiber density changes 
and neuronal hyper excitability. Along the axon, injuries 
such as trauma, compression, hypoxia, inflammation, 
overstimulation, and chemical damage can induce fiber 
degeneration and alterations in channel expression and 
composition, in turn resulting in ectopic firing and faulty 
signal transmission. In response to axonal damage and its 
sequelae, satellite glia and autonomic neurons can incur 
pain-promoting states though alterations in their overall 
numbers, distribution, sprouting patterns, and channel 
expression. In the Dorsal root ganglia and trigeminal ganglia, 
primary afferent cell bodies can be exposed to chemical, 
mechanical, and excitotoxic damage, and in neuropathic pain 
states shows maladaptive changes in their membrane 
composition, synapse properties, and synapse location(s). 
The probability of peripheral nerve damage or its 
progression to neuropathic pain can also be increased by 
genetic predispositions and/or hereditary condition. The 
final result of the maladaptive mechanisms undergoing 
peripheral nerve damage is a state of improper signaling 
from the peripheral neuron to its second-order targets, with 
multi-factorial1, 6 
MANAGEMENT AND TREATMENT OF 
NEUROPATHIC PAIN  
The IASP (International Association of the Study of Pain) 
say’s that neuropathic pain as “pain caused by a lesion or 
disease of the somatosensory system1-5,7,10 National Institute 
for Health and Care Excellence (NICE) guidance1 
recommends offering a choice of amitriptyline, duloxetine, 
gabapentin, or pregabalin as initial treatment, with switch-
ing between these drugs if pain relief is not obtained or the 
treatment not tolerated. A successful clinical management of 
pain requires balancing the advantages and side effects of 
available drugs, lifestyle interventions, and treating the 
underlying cause if possible. Possible comorbidities (anxiety, 
depression) need to be considered when choosing the best 
treatment for an individual patient.10 To treat myofascial 
pain and neuropathic pain in clinical practice, frequency-
specific microcurrent (FSM) has been used by numerous 
practitioners for more than 10 years in various specialties 
(MDs, DCs, NDs, PTs).9 
CLASSIFICATION OF DRUGS IN THE TREATMENT 
OF NEUROPATHIC PAIN 
1. First-line drugs 
 Tricyclic Antidepressants 
The mechanism of action lies on blocking the reuptake of 
norepinephrine and serotonin to pre-synaptic level, limiting 
the hyperalgesia induced by N-methyl-D-aspartate agonists, 
anti-histamine action on the H1 and H2 receptors, blockage 
of sodium channels that allows the stabilization of neuronal 
peripheral level and modulation of neuronal hyperactivity at 
central level, blockage of alpha receptors that can eliminate 
pain maintained by noradrenergic stimulation and 
stimulation of μ-opioid receptors (despite the low affinity) ]. 
The more relevant agents in this context are the tertiary 
amines such as amitriptyline and imipramine and the 
secondary amines such as nortriptyline (better tolerated). 
They may be used in the treatment of post herpetic 
neuralgia, painful diabetic neuropathy1,3, The most common 
side effects are sedation, confusion, anxiety, anticholinergic 
effects such as dry mouth, increased intra ocular pressure, 
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constipation, urinary retention, and orthostatic 
hypotension.1,3,10,11 Treatment starts with low doses and 
should be titrated slowly until there is an adequate control 
of pain. 
 
 Serotonin-norepinephrine reuptake inhibitors 
This agent are potent inhibitors of the reuptake serotonin 
and norepinephrine. Weak inhibitory action on dopamine 
reuptake is showed by both venlafaxine and duloxetine1,5,10. 
These drugs present favorable results in the treatment of 
neuropathic pain in multiple randomized controlled trial 
commonly in diabetic polyneuropathy, HIV neuropathy and 
oncologic neuropathic pain. The adverse effects include 
nausea, vomiting, constipation, somnolence, dry mouth, 
hyperhidrosis, loss of appetite weakness. Asthenia, fatigue, 
sedation, drowsiness and tremors. 1,5,10,13 
 
 Calcium channel α2-δ ligands 
The union of the gabapentin and pregabalin to the subunit 
α2-δ of calcium channels voltage dependent decreases the 
release of glutamate, norepinephrine and substance P, 
decreasing the neuronal excitability. The adverse reactions 
that may limit their use include drowsiness, dizziness and 
peripheral edema, which can be reduced with gradual dose 
titration. Treatment starts with low doses and several weeks 
may be required to achieve the effective dose. Special 
precautions are necessary in patients with renal 
insufficiency. 13,14 
 
 Carbamazepine 
This drug is a classic antiepileptic, which blocks voltage-
dependent sodium channels, inhibiting repetitive neuronal 
discharges and the propagation of synaptic excitatory 
impulses  in depolarized neurons .Carbamazepine is the 
first-line to treat the trigeminal .Common side effects 
resulting from the administration of carbamazepine include 
drowsiness, ataxia, dizziness, nausea, fatigue and skin 
reactions Hematologic changes such as aplastic anemia, 
leukopenia and thrombocytopenia can also arise. Caution in 
advised in patients with impaired hepatic function. 13 
 
 Lidocaine 
Lidocaine is a local anesthetic that causes a blockage of the 
movement of sodium ions to the interior of the membranes, 
causing a reversible blockade in the propagation of the pulse 
along the nerve fibers. Lidocaine 5% patches are the 
formulation most widely studied, constituting therapeutic 
option with proven effectiveness in peripheral neuropathies 
and allodynia, even in combination with other first-line 
drugs the adverse effects include skin rash, erythema, 
burning sensation and itching. 3 
 
2. Second-line drugs 
 Opioids 
The benefit of opioids is constantly justified in the literature, 
in a variety of central and peripheral conditions such as post 
herpetic neuralgia, diabetic neuropathy and phantom limb 
neuropathy. The most common adverse reactions include 
constipation, nausea, vomiting, dizziness, drowsiness, 
headache and dry mouth. Provides the possibility of 
addiction and modification of the behavioral pattern. 
Opioids are regarded as second-line treatment due to their 
side effects, compared with tricyclic antidepressants or 
anticonvulsants. Furthermore, systematic study has not 
performed on the safety of long term treatment. Within this 
group, the drugs used are the fentanyl and morphine.1,2,17,18 
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 Tramadol 
Tramadol has a dual mechanism of pharmacological action 
which consists of agonist activity on the μ-receptors, 
although this affinity is much lower than the effect exerted 
by morphine. On the other hand, tramadol blocks synaptic 
reuptake of the amines, which results in similar effects to 
those of inhibitors of monoaminoxidase. The reuptake of 
norepinephrine and serotonin in central nervous system is 
inhibited by tramadol, preventing the transmission of the 
pain through the medulla. Patients with different types of 
neuropathy, such as diabetic polyneuropathy and post 
herpetic neuralgia felt less pain and improvement in quality 
of life following tramadol treatment. The risk of abuse of 
tramadol is also present with the opioids. The adverse 
reactions develop from tramadol administration are 
common to opioids. The administration of tramadol may 
introducing seizures in patients with history of seizures and 
their association with the serotoninergic drugs such as 
duloxetine, venlafaxine, fluoxetine, paroxetina among others, 
may increase the risk of serotonin syndrome. 13 
 
3. Third-line drugs 
 Antidepressants 
It a weak evidence that the use of serotonin reuptake 
inhibitors in the treatment of neuropathic pain, as released 
by a Cochrane review. Other antidepressants such as 
citalopram and paroxetine had positive effects in diabetic 
polyneuropathy, whereas fluoxetine did not put forward any 
benefit. With benefit in some neuropathic condition, 
Bupropion inhibits the reuptake of dopamine and 
norepinephrine. The adverse effects of serotonin reuptake 
inhibitors include nausea, vomiting, drowsiness, dizziness, 
agitation and tremors, with special caution in patients with 
risk of seizures, suicide and glaucoma. The adverse reactions 
given by Bupropion such as insomnia, anorexia, agitation, 
headaches and tinnitus. Clinical trials shows that citalopram, 
paroxetine and bupropion may constitute a therapeutic line 
when the tricyclic antidepressants and inhibitors of 
reuptake of serotonin and norepinephrine are not effective. 3 
 
 Anticonvulsants 
To reduce the ectopic discharges in injured nerves the action 
of Antiepileptic drugs lies on stabilization of neuronal 
membrane, through various kind of mechanisms depending 
on the type of drug. In general, antiepileptic drugs facilitate 
inhibitory neurotransmission (GABA), reduce the excitatory 
neurotransmitter (glutamate) and modulate ionic channels 
existing in neuronal membrane (block sodium and calcium 
channels and activation of potassium channels. Lamotrigine 
stabilizes the neuronal membrane by acting on the voltage-
gated sodium channels. In three studies it was observed that 
valproic acid obtained positive results for diabetic 
polyneuropathy and postherpetic neuralgia, however, 
negative results obtained from other randomized clinical 
study. In patients with diabetic polyneuropathy, three 
randomized controlled clinical trials of oxcarbazepine were 
published, one of which was positive and the other two 
negative. Carbamazepine is the first-line treatment of 
trigeminal neuralgia, but in other clinical conditions 
evidence is limited. These drugs are therapeutic options 
when patients do not respond to first or second-line 
treatment. 1,3 
 
CONCLUSION 
The available data clearly indicates that clinical management 
on Neuropathic pain treatment is varying according to line 
of a drug treated. The available drug treatment for 
neuropathic pain includes first, second and third line drugs. 
It is shown that Neuropathic pain is generated by electrical 
excitation of neurons along with the pain pathways. A 
successful clinical management for neuropathic pain 
requires balancing the advantages and side effects of 
available drugs, lifestyle interventions, and treating the 
undergoing cause if possible for the management of 
neuropathic pain requires various line of treatment i.e first 
line and second line treatment which includes various types 
of drugs     
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